$GILD Recent Headlines AbbVie shares up on Hepat
Post# of 5325
Posted On: 11/24/2013 7:14:48 PM
$GILD Recent Headlines
AbbVie shares up on Hepatitis C results, but gains may be muted 11:49 a.m. Nov. 18, 2013 - Russ Britt
Dan Loeb ups stake in FedEx, Google, trims Yahoo 5:41 p.m. Nov. 14, 2013 - Sital S. Patel
Selling in growth-stock leaders continues 11:23 a.m. Oct. 31, 2013 - The Trading Deck
LinkedIn, Yelp decline; Baidu rallies after hours 5:14 p.m. Oct. 29, 2013 - Wallace Witkowski
Gilead profit up 17% as HIV drugs top sales growth 4:07 p.m. Oct. 29, 2013 - MarketWatch.com
Gilead shares rise 1% in late trading 3:59 p.m. Oct. 29, 2013 - Laura Mandaro
Earnings season focus shifts to revenue, capex 8:53 a.m. Oct. 27, 2013 - Wallace Witkowski
Healthcare stocks fall from first place in race for year's best-performing sector 2:32 p.m. Oct. 24, 2013 - blogs.marketwatch.com
In focus: Overbought conditions abound 7:21 p.m. Oct. 23, 2013 - Lawrence G. McMillan
Best Buy tops S&P 500; Netflix snaps losing streak 3:21 p.m. Oct. 10, 2013 - Sue Chang
Best Buy, Gilead Sciences lead S&P 500 gainers 3:05 p.m. Oct. 10, 2013 - Polya Lesova
Gilead, Acura stand out on up day for stocks, Quest tumbles 10:27 a.m. Oct. 10, 2013 - Russ Britt
Gilead ends leukemia study after positive results 4:10 p.m. Oct. 9, 2013 - MarketWatch.com
Citrix, Ruby Tuesday shares fall after hours 4:06 p.m. Oct. 9, 2013 - Wallace Witkowski
10 popular health-care stocks among hedge funds 11:34 a.m. Sept. 4, 2013 - Insider Monkey
Charting a market divergence 10:21 a.m. Aug. 22, 2013 - Michael Ashbaugh
Earnings help McKesson, hospitals; FDA ruling hits Vertex, aids Gilead 9:52 a.m. July 26, 2013 - Russ Britt
S&P 500 up another 5% in 2013: J.P. Morgan's Thomas Lee 8:36 a.m. July 26, 2013 - blogs.marketwatch.com
Gilead soars on rival Vertex's drug-ruling misfortune 4:47 p.m. July 25, 2013 - Russ Britt
Updates, advisories and surprises 4:31 p.m. July 25, 2013 - MarketWatch
Cramer's Mad Money - 11 Things To Watch In The Week Ahead (11/22/13) 6:24 a.m. Today - Seeking Alpha
Gilead And AbbVie Battle For Top Spot In $20 Billion Hepatitis Drug Market 4:37 a.m. Today - Seeking Alpha
Jim Cramer's Top Stock Picks: WDAY PANW GILD CELG BIIB REGN HD LOW JCI 6:00 a.m. Nov. 23, 2013 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan 8:05 p.m. Nov. 22, 2013 - TheStreet.com
Upside for Biogen, Gilead may be hard to come by: Barron's 3:46 p.m. Nov. 22, 2013 - Seeking Alpha
Recent Cloud IPO Veeva Systems Scores In Health Biz 3:31 p.m. Nov. 22, 2013 - Investors Business Daily
Biogen, Gilead, Celgene Drugs Get Thumbs Up In Europe 3:24 p.m. Nov. 22, 2013 - Investors Business Daily
Biogen & Gilead: Time To Ring the Cash Register? 2:37 p.m. Nov. 22, 2013 - Barrons.com
UPDATE: Bank of America Increased Gilead Sciences PT 2:23 p.m. Nov. 22, 2013 - benzinga.com
Time Warner Is the Belle of the Ball: Comcast a Potential Suitor 2:11 p.m. Nov. 22, 2013 - Wall St. Cheat Sheet
Biotech Stocks Underperforming? These Charts Says Otherwise 12:52 p.m. Nov. 22, 2013 - TheStreet.com
Gilead Hepatitis C Drug Wins EU Panel Vote Early 10:28 a.m. Nov. 22, 2013 - Investors Business Daily
Gilead Stock Hits New 52-Week High (GILD) 10:11 a.m. Nov. 22, 2013 - TheStreet.com
Analysts: Gilead Estimates Raised Following Initial Drug Pricing and 3 More Research Notes to Read 10:05 a.m. Nov. 22, 2013 - Wall St. Cheat Sheet
Catalyst Alert: 2 Biotech Giants Receive Positive CHMP Opinions 10:02 a.m. Nov. 22, 2013 - Seeking Alpha
Gilead (GILD) Rising Before The Market Opens 8:50 a.m. Nov. 22, 2013 - TheStreet.com
Top Analyst Upgrades and Downgrades: Gilead, Gogo, Micron, Target, Windstream and More 7:56 a.m. Nov. 22, 2013 - 247WallSt.com
Biotech Stock Mailbag: Enanta, Vanda, Pharmacyclics, Top 2014 Stock Catalysts 6:00 a.m. Nov. 22, 2013 - TheStreet.com
Must-Own Biotech Just Issued a New Buy Signal 8:25 p.m. Nov. 21, 2013 - InvestorPlace.com
Stock Market News for November 21, 2013 - Market News 10:06 a.m. Nov. 21, 2013 - Zacks.com
European CHMP Adopts Positive Opinion for Gilead Sciences' Sovaldi(R) for the Treatment of Chronic Hepatitis C Infection 8:47 a.m. Nov. 22, 2013 - BusinessWire
Stock Price Movement, Grants for Projects, and Clinical Data Presentations - Research Report on Gilead, Bristol-Myers Squibb, HCA, Allergan, and Alexion 8:00 a.m. Nov. 20, 2013 - PR Newswire
Gilead's Idelalisib Significantly Reduces Rate of Disease Progression or Death in Phase 3 Chronic Lymphocytic Leukemia Study 9:17 a.m. Nov. 18, 2013 - BusinessWire
European Commission Approves Gilead's Vitekta(TM), an Integrase Inhibitor for the Treatment of HIV-1 Infection 8:00 a.m. Nov. 18, 2013 - BusinessWire
Gilead Sciences to Present at the Credit Suisse 2013 Healthcare Conference on Wednesday, November 13 4:31 p.m. Nov. 12, 2013 - BusinessWire
Insider Trading Reports for Facebook, Microsoft, Gilead Sciences, Bank of America, Riverbed, and Wells Fargo 8:55 a.m. Nov. 11, 2013 - PR Newswire
S.F. Voters Repudiate Gilead, Other Pharma's Greed with Prop. D Victory 7:47 p.m. Nov. 7, 2013 - BusinessWire
Gilead to Present Data on Oncology Pipeline at American Society of Hematology Annual Meeting 9:00 a.m. Nov. 7, 2013 - BusinessWire
Clinical Trial Data, New Publications, Promotions, Financial Results and FDA Acknowledgements - Research Report on Gilead, Amgen, ACADIA Pharmaceuticals, ViroPharma, and MannKind 8:00 a.m. Nov. 6, 2013 - PR Newswire
Under AAAResearchReports.com Microscope: Gilead Sciences Inc., NPS Pharma Inc., Halozyme Therapeutics Inc., and InterMune Inc. 11:14 a.m. Nov. 4, 2013 - PR Newswire
Quarterly Financial Reports, Clinical Study Results, and R&D Events for the Investment Community - Research Report on Gilead Sciences, Clovis, Theravance, Charles River, and Acorda 8:00 a.m. Nov. 4, 2013 - PR Newswire
Gilead Announces New Sustained Viral Response Data for Sofosbuvir-Based Regimens in Genotype 3-Infected Hepatitis C Patients 9:01 a.m. Nov. 2, 2013 - BusinessWire
Gilead Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based Regimen for the Treatment of Hepatitis C in Patients Co-Infected With HIV 9:01 a.m. Nov. 2, 2013 - BusinessWire
Gilead Announces Phase 2 Results for Sofosbuvir-Based Regimens in Hepatitis C Patients Before and After Liver Transplantation 9:01 a.m. Nov. 2, 2013 - BusinessWire
Dun & Bradstreet CEO Sara Mathew Named Top S&P 500 Wealth Creator in 2013 8:30 a.m. Oct. 31, 2013 - PR Newswire
Sector Leaders Briefing & Capital Raise News: Muscle Warfare, Baidu, Herblife, Gilead Sciences and ARIAD 9:08 a.m. Oct. 30, 2013 - PR Newswire
Gilead Sciences Announces Third Quarter 2013 Financial Results 4:02 p.m. Oct. 29, 2013 - BusinessWire
Critical Alerts For Gilead Sciences, Trina Solar, T Rowe Price, Suncor Energy, and Morgan Stanley Released By InvestorsObserver 9:31 a.m. Oct. 29, 2013 - PR Newswire
The Non-Hodgkin's Lymphoma Drug Market Will Nearly Double to More Than $10 Billion by 2022 9:00 a.m. Oct. 28, 2013 - PR Newswire
FDA Advisory Committee Supports Approval of Gilead's Sofosbuvir for Chronic Hepatitis C Infection 4:43 p.m. Oct. 25, 2013 - BusinessWire
AbbVie shares up on Hepatitis C results, but gains may be muted 11:49 a.m. Nov. 18, 2013 - Russ Britt
Dan Loeb ups stake in FedEx, Google, trims Yahoo 5:41 p.m. Nov. 14, 2013 - Sital S. Patel
Selling in growth-stock leaders continues 11:23 a.m. Oct. 31, 2013 - The Trading Deck
LinkedIn, Yelp decline; Baidu rallies after hours 5:14 p.m. Oct. 29, 2013 - Wallace Witkowski
Gilead profit up 17% as HIV drugs top sales growth 4:07 p.m. Oct. 29, 2013 - MarketWatch.com
Gilead shares rise 1% in late trading 3:59 p.m. Oct. 29, 2013 - Laura Mandaro
Earnings season focus shifts to revenue, capex 8:53 a.m. Oct. 27, 2013 - Wallace Witkowski
Healthcare stocks fall from first place in race for year's best-performing sector 2:32 p.m. Oct. 24, 2013 - blogs.marketwatch.com
In focus: Overbought conditions abound 7:21 p.m. Oct. 23, 2013 - Lawrence G. McMillan
Best Buy tops S&P 500; Netflix snaps losing streak 3:21 p.m. Oct. 10, 2013 - Sue Chang
Best Buy, Gilead Sciences lead S&P 500 gainers 3:05 p.m. Oct. 10, 2013 - Polya Lesova
Gilead, Acura stand out on up day for stocks, Quest tumbles 10:27 a.m. Oct. 10, 2013 - Russ Britt
Gilead ends leukemia study after positive results 4:10 p.m. Oct. 9, 2013 - MarketWatch.com
Citrix, Ruby Tuesday shares fall after hours 4:06 p.m. Oct. 9, 2013 - Wallace Witkowski
10 popular health-care stocks among hedge funds 11:34 a.m. Sept. 4, 2013 - Insider Monkey
Charting a market divergence 10:21 a.m. Aug. 22, 2013 - Michael Ashbaugh
Earnings help McKesson, hospitals; FDA ruling hits Vertex, aids Gilead 9:52 a.m. July 26, 2013 - Russ Britt
S&P 500 up another 5% in 2013: J.P. Morgan's Thomas Lee 8:36 a.m. July 26, 2013 - blogs.marketwatch.com
Gilead soars on rival Vertex's drug-ruling misfortune 4:47 p.m. July 25, 2013 - Russ Britt
Updates, advisories and surprises 4:31 p.m. July 25, 2013 - MarketWatch
Cramer's Mad Money - 11 Things To Watch In The Week Ahead (11/22/13) 6:24 a.m. Today - Seeking Alpha
Gilead And AbbVie Battle For Top Spot In $20 Billion Hepatitis Drug Market 4:37 a.m. Today - Seeking Alpha
Jim Cramer's Top Stock Picks: WDAY PANW GILD CELG BIIB REGN HD LOW JCI 6:00 a.m. Nov. 23, 2013 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan 8:05 p.m. Nov. 22, 2013 - TheStreet.com
Upside for Biogen, Gilead may be hard to come by: Barron's 3:46 p.m. Nov. 22, 2013 - Seeking Alpha
Recent Cloud IPO Veeva Systems Scores In Health Biz 3:31 p.m. Nov. 22, 2013 - Investors Business Daily
Biogen, Gilead, Celgene Drugs Get Thumbs Up In Europe 3:24 p.m. Nov. 22, 2013 - Investors Business Daily
Biogen & Gilead: Time To Ring the Cash Register? 2:37 p.m. Nov. 22, 2013 - Barrons.com
UPDATE: Bank of America Increased Gilead Sciences PT 2:23 p.m. Nov. 22, 2013 - benzinga.com
Time Warner Is the Belle of the Ball: Comcast a Potential Suitor 2:11 p.m. Nov. 22, 2013 - Wall St. Cheat Sheet
Biotech Stocks Underperforming? These Charts Says Otherwise 12:52 p.m. Nov. 22, 2013 - TheStreet.com
Gilead Hepatitis C Drug Wins EU Panel Vote Early 10:28 a.m. Nov. 22, 2013 - Investors Business Daily
Gilead Stock Hits New 52-Week High (GILD) 10:11 a.m. Nov. 22, 2013 - TheStreet.com
Analysts: Gilead Estimates Raised Following Initial Drug Pricing and 3 More Research Notes to Read 10:05 a.m. Nov. 22, 2013 - Wall St. Cheat Sheet
Catalyst Alert: 2 Biotech Giants Receive Positive CHMP Opinions 10:02 a.m. Nov. 22, 2013 - Seeking Alpha
Gilead (GILD) Rising Before The Market Opens 8:50 a.m. Nov. 22, 2013 - TheStreet.com
Top Analyst Upgrades and Downgrades: Gilead, Gogo, Micron, Target, Windstream and More 7:56 a.m. Nov. 22, 2013 - 247WallSt.com
Biotech Stock Mailbag: Enanta, Vanda, Pharmacyclics, Top 2014 Stock Catalysts 6:00 a.m. Nov. 22, 2013 - TheStreet.com
Must-Own Biotech Just Issued a New Buy Signal 8:25 p.m. Nov. 21, 2013 - InvestorPlace.com
Stock Market News for November 21, 2013 - Market News 10:06 a.m. Nov. 21, 2013 - Zacks.com
European CHMP Adopts Positive Opinion for Gilead Sciences' Sovaldi(R) for the Treatment of Chronic Hepatitis C Infection 8:47 a.m. Nov. 22, 2013 - BusinessWire
Stock Price Movement, Grants for Projects, and Clinical Data Presentations - Research Report on Gilead, Bristol-Myers Squibb, HCA, Allergan, and Alexion 8:00 a.m. Nov. 20, 2013 - PR Newswire
Gilead's Idelalisib Significantly Reduces Rate of Disease Progression or Death in Phase 3 Chronic Lymphocytic Leukemia Study 9:17 a.m. Nov. 18, 2013 - BusinessWire
European Commission Approves Gilead's Vitekta(TM), an Integrase Inhibitor for the Treatment of HIV-1 Infection 8:00 a.m. Nov. 18, 2013 - BusinessWire
Gilead Sciences to Present at the Credit Suisse 2013 Healthcare Conference on Wednesday, November 13 4:31 p.m. Nov. 12, 2013 - BusinessWire
Insider Trading Reports for Facebook, Microsoft, Gilead Sciences, Bank of America, Riverbed, and Wells Fargo 8:55 a.m. Nov. 11, 2013 - PR Newswire
S.F. Voters Repudiate Gilead, Other Pharma's Greed with Prop. D Victory 7:47 p.m. Nov. 7, 2013 - BusinessWire
Gilead to Present Data on Oncology Pipeline at American Society of Hematology Annual Meeting 9:00 a.m. Nov. 7, 2013 - BusinessWire
Clinical Trial Data, New Publications, Promotions, Financial Results and FDA Acknowledgements - Research Report on Gilead, Amgen, ACADIA Pharmaceuticals, ViroPharma, and MannKind 8:00 a.m. Nov. 6, 2013 - PR Newswire
Under AAAResearchReports.com Microscope: Gilead Sciences Inc., NPS Pharma Inc., Halozyme Therapeutics Inc., and InterMune Inc. 11:14 a.m. Nov. 4, 2013 - PR Newswire
Quarterly Financial Reports, Clinical Study Results, and R&D Events for the Investment Community - Research Report on Gilead Sciences, Clovis, Theravance, Charles River, and Acorda 8:00 a.m. Nov. 4, 2013 - PR Newswire
Gilead Announces New Sustained Viral Response Data for Sofosbuvir-Based Regimens in Genotype 3-Infected Hepatitis C Patients 9:01 a.m. Nov. 2, 2013 - BusinessWire
Gilead Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based Regimen for the Treatment of Hepatitis C in Patients Co-Infected With HIV 9:01 a.m. Nov. 2, 2013 - BusinessWire
Gilead Announces Phase 2 Results for Sofosbuvir-Based Regimens in Hepatitis C Patients Before and After Liver Transplantation 9:01 a.m. Nov. 2, 2013 - BusinessWire
Dun & Bradstreet CEO Sara Mathew Named Top S&P 500 Wealth Creator in 2013 8:30 a.m. Oct. 31, 2013 - PR Newswire
Sector Leaders Briefing & Capital Raise News: Muscle Warfare, Baidu, Herblife, Gilead Sciences and ARIAD 9:08 a.m. Oct. 30, 2013 - PR Newswire
Gilead Sciences Announces Third Quarter 2013 Financial Results 4:02 p.m. Oct. 29, 2013 - BusinessWire
Critical Alerts For Gilead Sciences, Trina Solar, T Rowe Price, Suncor Energy, and Morgan Stanley Released By InvestorsObserver 9:31 a.m. Oct. 29, 2013 - PR Newswire
The Non-Hodgkin's Lymphoma Drug Market Will Nearly Double to More Than $10 Billion by 2022 9:00 a.m. Oct. 28, 2013 - PR Newswire
FDA Advisory Committee Supports Approval of Gilead's Sofosbuvir for Chronic Hepatitis C Infection 4:43 p.m. Oct. 25, 2013 - BusinessWire
(0)
(0)Scroll down for more posts ▼